Further Reading

Wednesday, 20 November 2024

Vaccine stocks plummet after RFK Jr. nominated as HHS secretary

 Pharmaceutical stocks are in free fall following President Donald Trump’s nomination of Robert F. Kennedy Jr. as secretary of Health and Human Services (HHS). Shares of Moderna (-30.6%), Novavax (-42.7%), and BioNTech (-11.9%) dropped sharply in premarket trading after the announcement, reflecting concerns over a potential shift in U.S. health policy under Kennedy’s leadership.

The downward spiral continued into European markets, where shares of vaccine producers like Sanofi and GSK also saw losses. The dramatic plunge in stock prices is the latest indicator of the uncertainty sweeping through the biotechnology sector following RFK Jr.'s nomination. 

If RFK Jr. is approved by Congress for the new role, he will oversee the hopelessly corrupt Centers for Disease Control (CDC), the Food and Drug Administration (FDA), the National Institutes of Health (NIH) and a slew of other agencies.

Kennedy, a long-time advocate for children's health and environmental issues, has been one of the most vocal critics of vaccine policies in the U.S. He has publicly questioned the safety of vaccines and criticized the influence of pharmaceutical companies on public health, particularly the approval processes overseen by the Food and Drug Administration (FDA) and the propaganda underpinning the Centers for Disease Control’s (CDC) childhood vaccine schedule. He is perhaps best known for founding the nonprofit Children’s Health Defense, which analyzes medical and scientific literature and publishes compelling articles on the real health issues facing American families...<<<Read More>>>...